Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood-brain barrier

Journal of Biomaterials Applications

Volumn 27, Issue 7, 2013, Pages 909-922

  Chen, Yung Chu ^a   Hsieh, Wen Yuan ^a   Lee, Wen Fu ^b   Zeng, Ding Tai ^b  

^a INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

^b TATUNG UNIVERSITY   (Taiwan)

Author keywords

Blood brain barrier; drug delivery; loperamide; nanoparticles; poly (lactide co glycolide) Poly (ethylene glycol) Poly (lactide co glycolide)

Indexed keywords

ANTINOCICEPTION; ANTINOCICEPTIVE EFFECT; BLOOD-BRAIN BARRIER; BRAIN TISSUE; COATED NANOPARTICLES; IN-VITRO; LOPERAMIDE; MODEL DRUGS; NANOPARTICLE SYSTEMS; NANOPRECIPITATION METHOD; PAIN RESPONSE; PLGA NANOPARTICLES; POLOXAMER; POLY LACTIDE-CO-GLYCOLIDE; POLYSORBATE 80;

BLOCK COPOLYMERS; BLOOD; DRUG DELIVERY; EMULSIONS; FORMALDEHYDE; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; SURFACE ACTIVE AGENTS; SURFACE TREATMENT;

NANOPARTICLES;

ANTIDIARRHEAL AGENT; DRUG CARRIER; LACTIC ACID; LOPERAMIDE; MACROGOL DERIVATIVE; NANOPARTICLE; POLOXAMER; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; POLYSORBATE; SURFACTANT;

ANIMAL; ARTICLE; BLOOD BRAIN BARRIER; CELL LINE; CHEMISTRY; MALE; METABOLISM; MOUSE; RAT; SURFACE PROPERTY;

ANIMALS; ANTIDIARRHEALS; BLOOD-BRAIN BARRIER; CELL LINE; DRUG CARRIERS; LACTIC ACID; LOPERAMIDE; MALE; MICE; NANOPARTICLES; POLOXAMER; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; POLYSORBATES; RATS; SURFACE PROPERTIES; SURFACE-ACTIVE AGENTS;

MLCS; MLOWN;

EID: 84873690481     PISSN: 08853282     EISSN: 15308022     Source Type: Journal    
DOI: 10.1177/0885328211429495     Document Type: Article

References (49)

1. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychute K, Koch-Brandt C, Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target. 2002 ; 10: 317-325
2. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther. 2004 ; 104: 29-45
3. Ambrose J, Sheng HH. Blood-brain barrier drug discovery for central nervous system infections, current drug targets. Infectious Disorders. 2005 ; 5: 65-72
4. Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. Curr Med Chem Central Nervous Syst Agents. 2002 ; 2: 241-249
5. Kreuter J. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J Nanosci Nanotechnol. 2004 ; 4: 484-488
6. Beduneau A, Saulnier P, Benoit JP. Active targeting of brain tumors using nanocarriers. Biomaterials. 2007 ; 28: 4947-4967
7. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 2001 ; 47: 65-81
8. Petri B, Bootz A, Khalansky A, Hekmatara T, Muller R, Uhl R. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated Poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J Control Rel. 2007 ; 117: 51-58
9. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch BC. Apolipoprotein-mediated transport of nanoparticle-bound drugs across blood-brain barrier. J Drug Target. 2002 ; 10: 317-325
10. Debotton N, Pames M, Kadouche J, Benita S. Overcoming the formulation obstacles towards targeted chemotherapy: in vitro and in vivo evaluation of cytotoxic drug loaded immunonanoparticles. J Control Release. 2008 ; 127: 219-230
11. Nimpf J, Schneider WJ. From cholesterol transport to signal transduction: low density lipoprotein receptor, very low density lipoprotein receptor and apolipoprotein E Receptor-2, biochim. Biophys Acta. 2000 ; 1529: 287-298
12. Dergunov AD. Apolipoprotein E structure and substrate and receptor-binding activities of triglyceride-rich human plasma lipoproteins in normo- and hypertriglyceridemia. Biochemistry. 2004 ; 69: 720-737
13. Ribalta J, Vallve JC, Girona J, Masana L. Apolipoprotein and apolipoprotein receptor genes, blood lipids and disease. Curr Opin Clin Nutr Metab Care. 2003 ; 6: 177-187
14. Lucarelli M, et al. The expression of native and oxidized LDL receptors in brain microvessels is specifically enhanced by astrocytes-derived soluble factor(s). FEBS Letters. 2002 ; 522: 19-23
15. Kreuter J, Petrov VE, Kharkevich DA, Alyautdin RN. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J Controlled Release. 1997 ; 49: 81-87
16. Schroeder U, Sabel BA. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Research. 1996 ; 710: 121-124
17. Schroeder U, Sommerfeld P, Sabel BA. Efficacy of oral dalargin-loaded nanoparticle delivery across the blood-brain barrier. Peptides. 1998 ; 19: 777-780
18. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 1996 ; 674: 171-174
19. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Del Rev. 2001 ; 47: 65-81
20. Kreuter J. Application of nanoparticles for the delivery of drugs to the brain. Int Cong. Ser. 2005 ; 1277: 85-94
21. Gelperina SE, et al. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol Let. 2002 ; 126: 131-141
22. Friese A, Seiller E, Quack G, Lorenz B, Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur J Pharma Biopharma. 2000 ; 49: 103-109
23. Schroeder U, Sommerfeld P, Ulrich S, Sabel BA. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J Pharm Sci. 1998 ; 87: 1305-1307
24. Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J. Significant entry of tubocurarine into the brain of rats by adsorption topolysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brainperfusion study. J Microencapsul. 1998 ; 15: 67-74
25. Calvo P, et al. PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases. J Neurosci Meth. 2001 ; 111: 151-155
26. Svetlana G, et al. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur J Pharma Biopharma. 2010 ; 74: 157-163
27. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res. 1997 ; 14: 325-328
28. Jain RA, Rhodes CT, Railkar AM, Malick AW, Shah NH. ontrolled release of drugs from injectable in situ formed biodegradable plga microspheres: effect of various formulation variables. Eur J Pharm Biopharm. 2000 ; 50: 257-262
29. Duvvuri S, Janoria KG, Mitra AK. Development of a novel formulation containing poly(D,L-lactide-co-glycolide) microspheres dispersed in PLGA-PEG-PLGA gel for sustained delivery of ganciclovir. J Controlled Rel. 2005 ; 108: 282-293
30. Zhang Y, et al. A novel paclitaxel-loaded poly(e-caprolactone)/poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment. Acta Biomaterialia. 2010 ; 6: 2045-2052
31. Chee WG, Feng SS. Transferrin-conjugated nanoparticles of poly(lactide)-D-a-Tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials. 2010 ; 31: 7748-7757
32. Calvo P, et al. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur J Neurosci. 2002 ; 15: 1317-1326
33. Zentner GM, et al. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Controlled Rel. 2001 ; 72: 203-215
34. Roux F, Couraud PO. Rat brain endothelial cell lines for the study of blood-brain barrier permeability and transport functions. Cell Mol Neurobiol. 2005 ; 25: 41-58
35. Lagrange P, Romero IA, Minn A, Revest PA. Transendothelial permeability changes induced by free radicals in an in vitro model of the blood-brain barrier. Free Radic Biol Med. 27: 667-672
36. Dubuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effect of morphine, meperidine, and brain stem stimulation in rats and cats. Pain. 1977 ; 4: 161-174
37. Gref R, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Del Rev. 1995 ; 16: 215-233
38. Batrakova EV, Miller DW, Li S, Alakhov VY, Kabanov AV, Elmquist WF. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J Pharmacol Exp Ther. 2001 ; 296 (2). 551-557
39. Batrakova E, Li S, Vinogradov S, Alakhov V, Miller D, Kabanov A. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J Pharmacol Exp Ther. 2001 ; 299 (2). 483-493
40. Batrakova E, Li S, Miller D, Kabanov A. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm Res. 1999 ; 16 (9). 1366-1372
41. Mackay JA, Deen DF, Szoka FC. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res. 2005 ; 1035 (2). 139-153
42. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008 ; 57: 178-201
43. Michaelis K, et al. Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther. 2006 ; 317: 1246-1253
44. Dehouck B, Dehouck MP, Fruchart JC, Cecchelli R. Upregulation of the low density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes. J Cell Biol. 1994 ; 126: 465-473
45. Mardones P, et al. Alpha-tocopherol metabolism is abnormal in scavenger receptor class B type I (SR-BI)-seficient mice. J Nutr. 2002 ; 132: 443-449
46. Kreuter J, Gelperina S. Use of nanoparticles for cerebral cancer. Tumori. 2008 ; 94: 270-276
47. Schmauss C, Yaksh TL. In vivo studies on spinal opiate receptor systems mediating antinociception: II. Pharmacological profiles suggesting a differencial association of Mu, Delta and Kappa receptors with visceral, chemical and cutaneos thermal stimuli in the rat. J Pharmacol Exp Ther. 1984 ; 228: 1-12
48. Jensen TS, Yaksh TL. Comparison of antinociceptive action of morphine in the periaqueductal gray medial and paramedial medulla in rat. Brain Res. 1986 ; 363: 99-113
49. Elyad M, Davidson MD, Doursout MF, Peter S, Jacques E, Chelly MD. Antinociceptive and cardiovascular properties of esmolol following formalin injection in rats. Can J Anesth. 2001 ; 48: 59-64